Company intelligence / Profile preview

Libra Automotives

San Diego, California, United Stateseconomictimes.indiatimes.com ↗

Ownership: Private
Development stage: Other

Overview

Libra Therapeutics has three preclinical small molecule programs targeting neurodegenerative diseases. The lead candidate focuses on increasing autophagy via TRPML1 modulation to clear toxic proteins implicated in ALS and FTD. All programs are preclinical as of mid-2025, with the first expected to enter Phase 1 trials soon. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxam (discovery research organization providing chemical matter and assays)Multiple international CROs for R&D execution

Beyond the preview

Go deeper on Libra Automotives.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Automotives.

Explore the full profile